Dr. Vimal Prajapati reports on late breaking psoriasis developments from the 2023 EADV Congress in Berlin.

Dr. Mark Kirchoff reports lives from the 2023 EADV Congress in Berlin and gives insights into the pathogenesis of psoriasis.

Risankizumab is effective at achieving skin clearance in moderate-to-severe plaque psoriasis in bio-naive patients.

Race an ethnicity may not be associated with access to biologics for psoriasis patients in the United States.

Psoriasis and AD patients may have differing views on disease severity, a phenomenon known as discordant severity grading.

Approximately two thirds of psoriasis patients who received home narrowband UV-B therapy did not use systemic therapy or in-office UV-B

A study has linked metabolic syndrome, waist circumference, and hypertension to increased psoriasis risk.

Plaque psoriasis patients with darker skin tones treated with CAL/BDP cream respond similarly to the general study population.